This recombinant monoclonal antibody is a research-grade biosimilar to Ustekinumab-ttwe, designed to target IL12B, the p40 subunit shared by both interleukin-12 (IL-12) and interleukin-23 (IL-23). IL12B encodes a critical component of these pro-inflammatory cytokines that play essential roles in T-helper cell differentiation and immune responses. IL-12 promotes Th1 cell development and IFN-γ production, while IL-23 is crucial for Th17 cell maintenance and function. Dysregulation of IL12B-containing cytokines is implicated in various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and inflammatory bowel disease.
Ustekinumab-ttwe is an FDA-approved therapeutic antibody that neutralizes both IL-12 and IL-23 by binding to their shared p40 subunit, preventing receptor engagement and downstream signaling. This biosimilar antibody provides researchers with a valuable tool for investigating IL-12/IL-23 pathways, studying cytokine-mediated immune responses, and exploring mechanisms underlying chronic inflammatory diseases. It serves as an important reagent for immunological research and therapeutic mechanism studies.
Email: support@cusabio.com
Distributors Worldwide